
Vestex
Develops, manufacturers and markets textile products and technologies.
Date | Investors | Amount | Round |
---|---|---|---|
investor investor investor investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
N/A | €0.0 | round | |
$9.5m | Early VC | ||
Total Funding | 000k |
USD | 2022 | 2023 |
---|---|---|
Revenues | 0000 | 0000 |
EBITDA | 0000 | 0000 |
Profit | 0000 | 0000 |
EV | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x |
R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Vestex is a materials science company focused on developing and marketing advanced, active barrier protective fabrics. The company was founded in 2009 by Ben Favret III, who was inspired to create protective solutions for frontline healthcare workers regularly exposed to pathogens and fluids. Drawing from an extensive background in the healthcare industry, including roles at Pfizer and biotech startups, Favret led a team to develop the company's core technology.
The company's primary product is VESTEX®, a patented textile technology that incorporates a dual-action mechanism for protection. The outer surface of the fabric is fluid-repellent, designed to resist splatters and spills from substances like blood, urine, and sputum. This repellency acts as the first line of defense, minimizing the number of microorganisms that remain on the apparel. The fabric is then embedded with an EPA-registered antimicrobial agent that has been shown in laboratory and clinical settings to reduce Methicillin-resistant Staphylococcus aureus (MRSA) by over 99.9% on the fabric's surface. A significant milestone was achieved in May 2018, when VESTEX apparel received FDA 510(k) clearance as a Class II medical device, creating a new category for active barrier garments. This clearance was based on extensive testing that demonstrated its effectiveness in reducing MRSA accumulation on healthcare workers' clothing compared to conventional scrubs.
Vestex operates on a B2B and B2C model, primarily generating revenue through licensing agreements with manufacturers and selling its own branded apparel. The business model allows other companies to incorporate VESTEX® technology into their product lines, providing them access to the associated patents and regulatory clearances. The primary target market is the healthcare sector, supplying scrubs, lab coats, and other garments to hospitals and healthcare workers. However, the company is expanding into other markets where workers face exposure risks, including first responders, food service, and military personnel. The technology is also being positioned for consumer products like athletic wear, children's clothing, and home goods, appealing to a growing demand for safety and protection. Keywords: active barrier apparel, medical textiles, antimicrobial fabric, fluid repellent scrubs, FDA 510K cleared apparel, healthcare uniforms, infection control textiles, protective clothing, MRSA resistant fabric, Ben Favret, Vestagen Protective Technologies, patented textile technology, Class II medical device, healthcare worker safety, protective fabrics, fluid resistant clothing, antimicrobial scrubs, medical device apparel, hospital uniforms, food service uniforms, first responder apparel, pathogen protection, textile innovation, liquid repellent fabric